Metropolis Healthcare (METROPOLIS) Fundamentals 2026 — P/E 62.1x, Revenue Analysis | SniperIQ
Metropolis Healthcare (METROPOLIS) is a India-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ₹11,792 Crore, trading at ₹568.45 on the BSE. This SniperIQ fundamentals page covers Metropolis Healthcare's valuation (P/E 62.1x, P/B 7.8x), profitability (net margin 11.5%), revenue (₹1,646 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Metropolis Healthcare's market cap?
Metropolis Healthcare (METROPOLIS) has a market capitalization of approximately ₹11,792 Crore, trading at ₹568.45 on the BSE. Market cap moves with the live share price.
What is Metropolis Healthcare's P/E ratio?
Metropolis Healthcare's trailing twelve-month P/E ratio is 62.1x, with a price-to-book (P/B) of 7.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Metropolis Healthcare?
Metropolis Healthcare runs a net profit margin of 11.5%, a gross margin of 55.7%, and an operating margin of 25.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Metropolis Healthcare generate?
Metropolis Healthcare reported revenue of ₹1,646 Crore for fiscal year 2026, with net income of ₹190 Crore and earnings per share (EPS) of 9.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Metropolis Healthcare pay a dividend?
Metropolis Healthcare offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Metropolis Healthcare financially healthy?
Metropolis Healthcare carries a debt-to-equity ratio of 0.15x and a current ratio of 1.40x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Metropolis Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Metropolis Healthcare (METROPOLIS) the key facts are: market cap ₹11,792 Crore, P/E 62.1x, revenue ₹1,646 Crore, 52-week range 413-599.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Metropolis Healthcare's full fundamentals live
Get Metropolis Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.